A phase i trial of epstein-barr virus Gp350 vaccine for children with chronic kidney disease awaiting transplantation

Transplantation

Volumn 88, Issue 8, 2009, Pages 1025-1029

  Rees, Lesley ^a   Tizard, E Jane ^b   Morgan, Andrew J ^c   Cubitt, W David ^d   Finerty, Susan ^c   Oyewole Eletu, Titilade A ^a,j   Owen, Karen ^e   Royed, Collin ^a,k   Stevens, Servi J ^f,i   Shroff, Rukshana C ^a   Tanday, Manjit K ^g   Wilson, A Douglas ^c   Middeldorp, Jaap M ^f   Amlot, Peter L ^h   Steven, Neil M ^g  

^a Great Ormond Street Hospital for Sick Children NHS Trust   (United Kingdom)

^b BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^h ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^j Bridge Health Centre   (United Kingdom)

^k OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

Epstein Barr Virus; Post transplant lymphoproliferative disease; Vaccination.

Indexed keywords

ALUMINUM HYDROXIDE; AZATHIOPRINE; EPSTEIN BARR VIRUS VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; RECOMBINANT GLYCOPROTEIN GP350; RITUXIMAB; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ADOLESCENT; ANIMAL CELL; ARTICLE; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOGENICITY; INJECTION SITE REACTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK; SCHOOL CHILD; TREATMENT DURATION; VACCINATION; VIRUS INFECTION;

ADOLESCENT; ANIMALS; CHILD; CHILD, PRESCHOOL; CHO CELLS; CRICETINAE; CRICETULUS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN G; INFANT; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MEMBRANE GLYCOPROTEINS; VACCINES, SYNTHETIC; VIRAL MATRIX PROTEINS; VIRAL VACCINES;

EID: 70350437381     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b9d918     Document Type: Article

References (22)

1. Villeneuve PJ, Schaubel DE, Fenton SS, et al. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 2007; 7: 941.
2. Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5: 2894.
3. Smith JM, Rudser K, Gillen D, et al. Risk of lymphoma after renal transplantation varies with time: An analysis of the United States Renal Data System. Transplantation 2006; 81: 175.
4. Woodman CB, Collins SI, VavrusovaN, et al. Role of sexual behavior in the acquisition of asymptomatic Epstein-Barr virus infection: A longitudinal study. Pediatr Infect Dis J 2005; 24: 498.
5. Katz BZ, Raab-Traub N, Miller G. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases. J Infect Dis 1989; 160: 589.
6. Katz BZ, Saini U. Presence of the diffuse early antigen of Epstein-Barr virus in lymphomas and lymphoproliferative disorders. Am J Pathol 1992; 140: 1247.
7. Porcu P, Eisenbeis CF, Pelletier RP, et al. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8( + ) T-cell restoration. Blood2002; 100: 2341.
8. Rea D, Fourcade C, Leblond V, et al. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation 1994; 58: 317.
9. Morgan AJ. Epstein-Barr virus vaccines. Vaccine 1992; 10: 563.
10. Cleary ML, Epstein MA, Finerty S, et al. Individual tumors of multifo-cal EB virus-induced malignant lymphomas in tamarins arise from different B-cell clones. Science 1985; 228: 722.
11. Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immuno-genicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2007; 196: 1749.
12. Jackman WT, Mann KA, Hoffmann HJ, et al. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. Vaccine 1999; 17: 660.
13. Middeldorp JM, Herbrink P. Epstein-Barr virus specific marker molecules for early diagnosis of infectious mononucleosis. J Virol Methods 1988; 21: 133.
14. van Grunsven WM, Nabbe A, Middeldorp JM. Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein-Barr virus capsid antigen complex. J Med Virol 1993; 40: 161.
15. Stevens SJ, Pronk I, Middeldorp JM. Toward standardization of Epstein-Barr virus DNA load monitoring: Unfractionated whole blood as preferred clinical specimen. J Clin Microbiol 2001; 39: 1211.
16. Stevens SJ, Verkuijlen SA, Brule AJ, et al. Comparison of quantitative competitive PCR with LightCycler-based PCR for measuring Epstein-Barr virus DNA load in clinical specimens. J Clin Microbiol 2002; 40: 3986.
17. Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA loadin unfractionated whole blood isessential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 1165.
18. Stevens SJ, Vervoort MB, van den Brule AJ,etal. Monitoringofepstein-barr virus DNA load in peripheral blood by quantitative competitive PCR. J Clin Microbiol 1999; 37: 2852.
19. van Beek J, zur Hausen A, Kranenbarg EK, et al. A rapid and reliable enzyme immunoassay PCR-based screening method to identify EBV-carrying gastric carcinomas. Mod Pathol 2002; 15: 870.
20. Wilson AD, Morgan AJ. Indirect measurement of Epstein-Barr virus neutralising antibodies by ELISA. J Virol Methods 1998; 73: 11.
21. Jabs WJ, Hennig H, Kittel M, et al. Normalized quantification by realtime PCR of Epstein-Barr virus load in patients at risk for posttrans-plant lymphoproliferative disorders. J Clin Microbiol 2001; 39: 564.
22. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine 2007; 25: 3752